Sorafenib blocks the activation of the HIF-2?/VEGFA/EphA2 pathway, and inhibits the rapid growth of residual liver cancer following high-intensity focused ultrasound therapy in vivo

Wu, L; Zhou, J; Zhou, WB; Huang, XF; Chen, QH; Wang, W; Zhai, LL; Li, SW; Tang, ZG

Tang, ZG (corresponding author), Wuhan Univ, Renmin Hosp, Dept Pancreat Surg, Wuhan 430060, Wuhan Province, Peoples R China.

PATHOLOGY RESEARCH AND PRACTICE, 2021; 220 ():